The FDA revises requirements for levothyroxine products

被引：10

作者：

Burman, Kenneth ^{[1
,2
]}

Hennessey, James ^{[3
]}

McDermott, Michael ^{[4
]}

Wartofsky, Leonard ^{[1
,2
]}

Emerson, Charles ^{[5
]}

机构：

[1] Georgetown Univ, Washington, DC 20057 USA

[2] Univ Hlth Sci, Bethesda, MD USA

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Univ Colorado, Denver, CO 80202 USA

[5] Univ Massachusetts, Worcester, MA 01605 USA

来源：

THYROID | 2008年 / 18卷 / 05期

关键词：

D O I：

10.1089/thy.2008.0109

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：487 / 490

页数：4

共 50 条

[41] Confusion over levothyroxine settled - FDA sets date for compliance
Murphy, JC
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (16) : 1476 - 1476
[42] Unithroid becomes first levothyroxine tablet to gain FDA approval
Traynor, K
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (19) : 1736 - 1737
[43] Japan's PMDA revises precautions for multiple products
Reactions Weekly, 2017, 1661 (1) : 4 - 4
[44] Increased levothyroxine requirements in critically ill patients with hypothyroidism
Imberti, R.
Ferrari, M.
Albertini, R.
Rizzo, V.
Tinelli, C.
MINERVA ANESTESIOLOGICA, 2010, 76 (07) : 500 - 503
[45] Increasing Levothyroxine Requirements in a Patient with Previously Stable Hypothyroidism
Batool, M.
Cadogen, S.
Tun, T. Kyaw
Sreenan, S.
Denton, M.
McDermott, J. H.
IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 3) : 103 - 104
[46] EPA revises EPCRA section 313 reporting requirements for PBT chemicals
不详
HAZARDOUS WASTE CONSULTANT, 2000, 18 (01) : B14 - B23
[47] Levothyroxine: clinically important differences between products
Reactions Weekly, 2004, 1016 (1) : 2 - 2
[48] BIOPHARMACEUTICAL COMPARISON OF 2 LEVOTHYROXINE SODIUM PRODUCTS
BLOUIN, RA
CLIFTON, GD
ADAMS, MA
FOSTER, TS
FLUECK, J
CLINICAL PHARMACY, 1989, 8 (08): : 588 - 592
[49] POTENCY OF BRAND NAME AND GENERIC LEVOTHYROXINE PRODUCTS
STOFFER, SS
SZPUNAR, WE
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 244 (15): : 1704 - 1705
[50] GMP/FDA requirements to aseptic production
Langer, U
Mangel, A
PHARMAZEUTISCHE INDUSTRIE, 2002, 64 (04): : 375 - 383

← 1 2 3 4 5 →